WASHINGTON, DC – The American Clinical Laboratory Association (ACLA) today announced new hire Paul Sheives as the Vice President for Reimbursement and Regulatory Policy for the Washington, D.C.-based association that represents the nation’s leading clinical laboratories on federal and state government policies impacting the industry.
“Paul’s impressive professional experience is tailor-made for meeting ACLA’s mission to provide our members with timely information and expert counsel on regulatory and reimbursement policies impacting the day to day services of clinical labs across the country,” said Alan Mertz, President of ACLA. “Paul’s background in personalized medicine, reimbursement and Food and Drug Administration (FDA) regulatory issues will prove a tremendous asset as Congress continues to address legislation and regulation impacting diagnostic innovation.”
Mr. Sheives was formerly Director of Personalized Medicine and Diagnostics Policy at the Biotechnology Industry Organization (BIO), where he directed BIO’s diagnostics and personalized medicine policy and oversaw its Personalized Medicine and Diagnostics Working Group. An attorney by trade, prior to his four years at BIO, Mr. Sheives practiced law as a legal associate at two international law firms focusing on FDA regulation and reimbursement. He earned his law degree from Georgetown University Law Center, his Masters in Cell & Molecular Biology from the University of Texas Southwestern Medical Center, and a BS in microbiology from University of Texas at Arlington.
“Diagnostic innovation plays a key role as medical decisions more and more are determined at a molecular level and the advancement of treatments and cures are able to reach patients and improve outcomes,” said Mertz. “This is an exciting time to be a part of this industry that is at the forefront of medical innovation. ACLA is very pleased to have Paul Sheives join in the mission to ensure patient access to the care diagnostics help to deliver.”